Taro Pharmaceutical Industries (NYSE:TARO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research note issued to investors on Saturday morning. The brokerage issued a strong-buy rating on the stock.

Taro Pharmaceutical Industries Stock Performance

NYSE TARO opened at $42.97 on Friday. Taro Pharmaceutical Industries has a 12 month low of $32.67 and a 12 month high of $45.76. The stock has a market cap of $1.62 billion, a P/E ratio of 29.84 and a beta of 0.56. The stock’s fifty day moving average price is $42.55 and its 200-day moving average price is $42.17.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings data on Monday, May 20th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.31 by $0.12. Taro Pharmaceutical Industries had a return on equity of 3.75% and a net margin of 8.56%. The company had revenue of $164.94 million for the quarter, compared to analysts’ expectations of $156.10 million.

Institutional Investors Weigh In On Taro Pharmaceutical Industries

Several institutional investors have recently modified their holdings of TARO. California State Teachers Retirement System lifted its holdings in Taro Pharmaceutical Industries by 2.3% in the first quarter. California State Teachers Retirement System now owns 11,323 shares of the company’s stock valued at $479,000 after acquiring an additional 252 shares during the period. Harvest Management LLC lifted its holdings in Taro Pharmaceutical Industries by 3.9% in the fourth quarter. Harvest Management LLC now owns 7,380 shares of the company’s stock valued at $308,000 after acquiring an additional 274 shares during the period. Inspire Advisors LLC lifted its holdings in Taro Pharmaceutical Industries by 5.9% in the first quarter. Inspire Advisors LLC now owns 14,495 shares of the company’s stock valued at $614,000 after acquiring an additional 813 shares during the period. SG Americas Securities LLC lifted its holdings in Taro Pharmaceutical Industries by 24.5% in the fourth quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $195,000 after acquiring an additional 921 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Taro Pharmaceutical Industries by 77.9% in the first quarter. BNP Paribas Financial Markets now owns 4,107 shares of the company’s stock valued at $174,000 after acquiring an additional 1,799 shares during the period. 91.40% of the stock is owned by hedge funds and other institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.